IMMIX BIOPHARMA INC. - COMMON STOCK

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

07 2 2024 09:37:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

05 2 2024 22:30:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Proposed Public Offering of Common Stock

05 2 2024 15:20:11 提供 Nasdaq GlobeNewswire

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

24 1 2024 08:35:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

04 1 2024 09:34:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

18 12 2023 09:39:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

11 12 2023 09:36:00 提供 Nasdaq GlobeNewswire

Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit

30 11 2023 09:46:00 提供 Nasdaq GlobeNewswire

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

22 11 2023 09:19:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

21 11 2023 09:46:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

21 11 2023 09:46:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

06 11 2023 09:12:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

06 11 2023 08:40:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

26 10 2023 08:58:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

16 10 2023 09:05:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

03 10 2023 09:14:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

02 10 2023 08:06:00 提供 Nasdaq GlobeNewswire

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis

21 9 2023 08:55:00 提供 Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

19 9 2023 09:10:00 提供 Nasdaq GlobeNewswire

Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

07 9 2023 08:41:00 提供 Nasdaq GlobeNewswire